EFG Asset Management’s ChemoCentryx, Inc. CCXI Stock Holding History

EFG Asset Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-62,051	Closed	-$1.54M	–	204
2022 Q2	$1.54M	Buy	62,051 +8,550	+16%	+$188K	0.32%	99
2022 Q1	$1.34M	Sell	53,501 -478	-0.9%	-$13.4K	0.2%	145
2021 Q4	$1.97M	Buy	+53,979	New	+$1.89M	0.26%	115

Other funds holding CCXI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

EFG Asset Management's CCXI Position: Q3 2022 in Review

EFG Asset Management sold out of ChemoCentryx, Inc. (CCXI) in Q3 2022, closing a stake of 62,051 shares — an estimated $1.54M sold.

EFG Asset Management first reported a position in CCXI in Q4 2021 and held it in 3 quarters. The position peaked at $1.97M in Q4 2021. 217 funds tracked by Wall St. Rank hold CCXI as of Q3 2022.

EFG Asset Management reported no remaining ChemoCentryx, Inc. position as of Q3 2022 after selling out during the quarter.
EFG Asset Management sold 62,051 ChemoCentryx, Inc. shares in Q3 2022, an estimated $1.54M.
EFG Asset Management first reported a position in ChemoCentryx, Inc. in Q4 2021 and held it in 3 quarters.
EFG Asset Management's ChemoCentryx, Inc. position peaked at $1.97M in Q4 2021.
217 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2022.

Based on EFG Asset Management's 13F filing for Q3 2022, filed 28 Oct 2022.